[1]
B. Müllhaupt, “Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland”, Swiss Med Wkly, vol. 151, no. 0304, p. w20399, Jan. 2021.